## Azole Resistance Mechanisms in Candida **Key Point:** Upregulation of efflux pump genes (CDR1 and MDR1) is the most common mechanism of azole resistance in clinical Candida isolates, accounting for the majority of resistance cases. ### Mechanism of Efflux Pump-Mediated Resistance Candida species express ATP-binding cassette (ABC) transporters and major facilitator superfamily (MFS) pumps that actively extrude azole drugs from the fungal cell, reducing intracellular drug concentration below therapeutic levels. This is an acquired resistance mechanism that develops with prolonged azole exposure. ### Comparison of Resistance Mechanisms | Mechanism | Frequency | Mechanism | Clinical Relevance | |-----------|-----------|-----------|--------------------| | **Efflux pump upregulation** | Most common (60–70%) | CDR1, MDR1 overexpression | Develops with chronic azole use | | **CYP51 mutation** | Less common (20–30%) | Altered drug binding site | Often combined with efflux pumps | | **Decreased ergosterol** | Rare | Membrane composition change | Usually non-viable strains | | **β-glucan synthesis defect** | Very rare | Echinocandin resistance | Not primary azole resistance | **High-Yield:** In clinical practice, azole-resistant Candida isolates typically show **multidrug efflux pump upregulation** as the primary mechanism, especially in patients with recurrent or chronic candidiasis on prolonged azole therapy. **Clinical Pearl:** Patients with poorly controlled diabetes and chronic azole exposure (e.g., recurrent oral candidiasis) are at highest risk for selecting efflux pump-overexpressing strains. Switching to echinocandins or amphotericin B may be necessary. **Tip:** On NEET PG, when asked about azole resistance in Candida, think **efflux pumps first** — this is the most tested and clinically relevant mechanism. [cite:Tripathi Pharmacology Ch 52]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.